Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Amgen, Inc. Raises FY 2012 Guidance
Amgen, Inc. announced that for fiscal 2012, it expects otal revenues to be in the range of $16.9 billion to $17.2 billion and adjusted EPS to be in the range of $6.20 to $6.35.
Latest Developments for Amgen Inc
- Amgen Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
- Amgen Inc Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
- FDA Halts Trials Of Amgen Inc Drug In Children, Cites Death-Reuters
- Amgen Inc Updates FY 2015 Guidance To A Range In Line With Analysts' Estimates-Conference Call
Latest Key Developments in Biotechnology
- Oramed Pharmaceuticals Inc Receives FDA Clearance To Initiate Oral Insulin Trials In U.S.
- Cordlife Group Ltd Announces Proposed Acquisition Of CS Cell Technologies Pte. Ltd, Cordlife Stem Cell Technology Limited And Certain Assets Of P.T. Cordlife Indonesia From Cordlife Limited
- Stemline Therapeutics Inc Prices $60 Million Public Offering Of Common Stock
- Ambit Biosciences Corp Announces Pricing Of Initial Public Offering
- Share this
- Link this
- Digg this
Follow Reuters